Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3372 participants
OBSERVATIONAL
2023-04-01
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiovascular Risk Factors, Aging and Dementia
NCT03938727
Risk Prediction and Its Intelligent Assessment for Cognitive Impairment Among Community-dwelling Older Adults
NCT05385874
China Alzheimer's and Neurodegenerative Disorder Research
NCT04320368
Predicting the Conversion From Mild Cognitive Impairment to Dementia
NCT01823666
Cognitive Decline in AD
NCT03946930
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cognitive trajectory cohort
Th cognitive trajectory cohort, based on CLHLS dataset, will be used to evaluate the influence of cardiovascular risk factors on the cognitive trajectories among cognitively intact older adults
No interventions assigned to this group
neuroiming sample
The neuroiming sample, including cognitively intact older adults with MRI data, will be used to explore the potential mechanism of the cardiovascular risk factors and cognitive function.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. With normal cognitive function at baseline (score ≥ 18 on the Chinese version of Mini-Mental State Examination, MMSE);
3. Had at least one domain information about cardiovascular risk factors (hypertension, diabetes, dyslipidemia, obesity, exercise, diet and smoking) at baseline;
4. Completed cognitive function assessment at least twice during 3 waves following-up after baseline;
5. Provided informed consent voluntarily.
1. Aged 55-80;
2. Right-handed;
3. Primary school education or above, with normal communication ability;
4. No complaints of cognitive impairment or decline;
5. MMSE score ≥ 26;
6. Clinical dementia rating (CDR) =0;
7. Provided informed consent voluntarily.
Exclusion Criteria
2. had a history of dementia or MMSE score \< 18 at baseline;
3. Without more than once cognitive function assessment during the follow-up;
4. Refused to participate the survey.
For the neuroimaging sample, who would be enrolled by this study:
1. Severe visual or hearing impairment, difficult to complete cognitive function assessment;
2. Had contraindications to magnetic resonance examination, such as claustrophobia, cardiac pacemaker and artificial heart valve;
3. Had cardiovascular diseases (such as myocardial infarction and unstable angina pectoris), severe respiratory diseases, malignant tumors, renal failure and other serious physical diseases;
4. Had diseases that could affect cognitive function, such as hypothyroidism, syphilis, vitamin B12 deficiency and anemia;
5. Had a history of any mental disease;
6. Had a history of cerebrovascular disease, or obvious space occupying lesions in the brain revealed by magnetic resonance examination;
7. Refused to participate the survey.
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Sixth Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaozhen LV
Associate Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaozhen Lv
Role: PRINCIPAL_INVESTIGATOR
Peking University Six Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Six Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
82003539
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.